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As antiretroviral therapy (ART) becomes more widespread globally, it is important to 
investigate factors which have an effect on HIV progression in order to determine the 
best intervention for individual patients. Nutritional and inflammatory factors have 
recently been at the forefront of this investigation; however, their effect on CD4 recovery 




This study aims to determine nutritional and inflammatory markers that have an effect on 
CD4 recovery in a treatment-naïve HIV-positive cohort consisting of individuals in nine 




469 adults initiating ART in nine countries with CD4 count of <350 cells/mm
3
 were used 
for this analysis. Associations between baseline levels of nutritional and inflammatory 
biomarkers and longitudinal CD4 recovery were measured using a random-effects 
generalized least squares (GLS) linear model at 24 and 96 weeks. Logistic regression 
using generalized estimating equations (GEE) was used to examine the longitudinal 




Multivariate GLS analysis at week 24 revealed statistically significant associations 
between longitudinal CD4 recovery and low baseline levels of β-carotene and lycopene,  
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as well as 25(OH)-Vitamin D deficiency (decrease of 14.07 CD4 cells, p=0.027). At 96 
weeks, we observed statistically significant associations between CD4 recovery and 
lower levels of α-carotene and lycopene, increased levels of sCD14, and selenium 
deficiency (decrease of 24.01 CD4 cells, p=0.012). 25(OH)-Vitamin D deficiency was 
also trending significant (decrease of 17.89 CD4 cells, p=0.059). 
 
Using an adjusted GEE logistic regression model at 96 weeks, we found that Vitamin 
B12 deficiency was associated with a higher odds of CD4 non-recovery (OR=2.00, 
p=0.031); selenium deficiency was also significantly associated with worse CD4 




Our results show that baseline levels of nutritional biomarkers are associated with CD4 
recovery over time after ART initiation, especially selenium and 25(OH)-vitamin D. 
Although achieving optimal CD4 recovery after ART initiation remains a challenge in 
many areas of the world, understanding the relationship between nutritional deficiencies 
and CD4 recovery can help us to identify and appropriately monitor high-risk 
populations. 
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Human immunodeficiency virus (HIV) is one of the most devastating diseases for low- 
and middle-income countries, which accounted for 97% of the estimated 35.5 million 
HIV-positive individuals in 2012 [1]. An important indicator of HIV progression is a 
decrease in CD4
+
 T lymphocyte count (referred here as CD4 count); because HIV 
preferentially infects CD4 cells, CD4 count provides an immunologically relevant 
measure for disease progression [2]. CD4 recovery after initiation of antiretroviral 
therapy (ART) is essential for restoring immune function in HIV-positive individuals; 
however, CD4 recovery is variable in different individuals and many factors have been 
found to affect recovery. Differences by sex [3][4], race [5], geographic region [5], 
intravenous drug use [6], and alcohol use [7] can each affect the level of CD4 recovery, 
and their effects can vary by individual. Nutritional and inflammatory biomarkers are 
also currently being investigated for their relationship to HIV progression due to their 
potential antioxidant effects and effects on immune function. However, the roles of 
nutritional, inflammatory, and immune activation biomarkers in CD4 recovery after ART 
initiation have not been well studied, especially in low- and middle-income populations.  
 
Because much of the HIV epidemic is focused in areas with populations experiencing 
chronic undernourishment, the identification of specific nutritional and inflammation- 
related risk factors related to nutrition beyond BMI is a clear priority, as the combination 
of undernourishment and HIV infection is thought to have an additive negative effect [8]. 
The combination of this knowledge and the ever-improving tools to measure nutritional 
deficiencies has led to an increase in studies using serum biomarkers to identify risk 
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factors for worse HIV progression. Neopterin and β-2microglobulin, both serum 
biomarkers of immune activation, have been identified as strong predictors of HIV 
disease progression [9], and VCAM-1, a marker for endothelial activation, has been seen 
to be predictive of the risk of HIV-1 progression as well [10].  
 
Acute HIV infection is facilitated by the binding of the virus’ gp120 molecule to the CD4 
receptor on CD4 cells, as well as the binding of HIV’s gp20 molecule to the co-receptors 
CCR5 and CXCR4 [11]. Response of CD4 cells is known to be an important factor in the 
immune system’s ability to fight a viral infection, as these cells are responsible for 
sending signals to other areas of the body to recruit additional immune cells to fight the 
infection [12]. An initial decrease in CD4 cells shortly after the initial infection is 
followed by a rapid increase in the number of circulating CD4 cells soon after this 
depletion in response to the viral infection. This early CD4 activity is critical for the early 
containment of the virus and has been associated with an initial decrease of plasma viral 
load[12][13], However, this burst of immune activation can also have detrimental effects 
– it is hypothesized that persistent immune system hyperactivation can lead to the 
destruction of the naïve CD4 cell pool and CD4 cell depletion [14]. Over time, HIV-
positive individuals experience a decrease and eventual depletion of CD4 cells. Time to 
CD4 depletion varies by patient but is affected by factors such as HIV viral load and time 
of treatment initiation, if any [15].  
 
Because CD4 cells are preferentially targeted for infection by HIV, a depleted CD4 count 
is a typical characteristic of HIV-related immunosuppression [16][17]. CD4 depletion is 
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achieved via multiple pathways, from both direct (mediated by HIV) and indirect 
(mediated by the immune system) action of HIV; the two principal causes are destruction 
of mature CD4 cells and impaired production of naïve CD4 cells [16]. Destruction of 
mature CD4 cells is mediated by HIV-induced apoptosis, disruption of cell membranes, 
accumulation of unintegrated viral DNA, cytolysis and apoptosis by cytolytic T-cells or 
natural killer (NK) cells that recognize an HIV-infected cell, and autoimmune reactions 
derived from the humoral immune system, among other mechanisms [16]. Production of 
naïve CD4 cells can be impacted by HIV-mediated death of CD4 progenitor cells, 
disruption of immune signaling and cytokine production for cell production, and 
nonspecific HIV-related health problems and co-infections that cause decreased 
functionality of the immune system [16]. Because CD4 count is an immunological 
indicator of HIV disease progression, it is often used to determine treatment options; 
currently, the World Health Organization (WHO) recommends that all HIV-positive 
patients with CD4 count ≤500 cells/mm
3
 initiate ART [15][18].  
 
CD4 recovery after initiation of ART is a critical feature of restoring immune function in 
HIV-positive individuals. Monitoring patients’ CD4 changes once ART is started is an 
important indicator of how the patient is responding to the treatment; an increase of 
approximately 100 cells/mm
3
 is expected the first year on treatment, followed by 
subsequent increases of approximately 50 cells/mm
3
 per year after the first year [19][20]. 
Immunologic failure occurs when a patient fails to reach these CD4 benchmarks while 
simultaneously achieving viral suppression [20]. However, there is no formal consensus 
among clinicians as to what exactly defines an immunologic failure; immunologic 
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response is often complicated by AIDS-defining co-morbidities and the baseline CD4 
count of a patient, making one generalizable definition difficult [20].   
 
The overall objective of this study was to determine the effect of specific micronutrient 
deficiencies and elevated inflammatory biomarkers at treatment initiation on CD4 
recovery from both a short-term and a long-term standpoint. This information could be 
used in a clinical setting to determine the most effective combination of treatment and 




Study Description & Population 
Our study population was a stratified sample by country of the Prospective Evaluation of 
Antiretrovirals in Resource Limited Settings (PEARLS) trial, a randomized clinical trial 
examining once-daily versus twice-daily dosing of three ART regimens (AIDS Clinical 
Trials Group A5175, clinicaltrials.gov NCT00084136). In the parent trial, a total of 1,571 
participants were recruited between May 2005 and July 1007 from ACTG sites in Rio de 
Janeiro and Porto Alegre, Brazil (n=231, 14.7%); Port-au-Prince, Haiti (n=100, 6.4%); 
Chennai and Pune, India (n=255, 16.2%); Blantyre and Lilongwe, Malawi (n=221, 
14.1%); Lima, Peru (n=134, 8.5%); Durban and Johannesburg, South Africa (n=210, 
13.4%); Chiang Mai, Thailand (n=100, 6.4%); Harare, Zimbabwe (n=110, 7.0%); and all 
ACTG sites located in the United States (n=210, 13.4%). ACTG Sites in the United 
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States were located in major metropolitan areas, and individuals enrolled at these 
locations accounted for approximately 11.2% of all participants at baseline.  
 
In the parent trial, eligibility for inclusion was determined as ≥18 years, confirmed HIV-1 
infection, CD4 count of <300 cells/mm
3
, and less than one week of documented 
cumulative antiretroviral therapy at baseline. Potential participants with abnormally high 
or low values of absolute neutrophils, hemoglobin, creatinine clearance, or aspartate 
transaminase or alanine transaminase were excluded from the study. No pregnant women 
were included in the study; women of reproductive potential agreed to use at least one 
form of contraception. Enrollment of participants occurred via a centralized web-based 
system managed by the ACTG Data Management Center. Participants were randomized 
equally to the three treatment regimens: 1) efavirenz with twice-daily lamivudine-
zidovudine; 2) atazanavir with didanosine EC and emtricitabine (all given once daily); 
and 3) efavirenz with emtricitabine-tenofovir-DF once daily.  
 
For this analysis, we used a sample of 469 individuals chosen from the full cohort of 
1,571 individuals.  These 469 individuals consist of a previously chosen random 
subcohort from the parent trial (n=269) plus an additional 200 individuals for whom 
baseline biomarker data was available; these individuals were included to increase the 
statistical power of the analysis. In order to establish that these individuals were 
representative of the individuals included in the random subcohort, we compared their 





This study was approved by the Institutional Review Board at the Johns Hopkins School 
of Medicine as well as at local Institutional Review Boards in all other countries.  
 
Data Collection and Laboratory Analysis 
Participants at baseline underwent a thorough physical exam, medical history review, 
serum chemistries, liver function tests, CD4 count, and plasma HIV-1 RNA viral load. 
Serum collected at the baseline visit was stored at -80°C, and plasma HIV-1 RNA viral 
load was measured using Roche Amplicor Monitor Assay (v1.5, Branchburg, NJ).  Body 
mass index (BMI) was calculated at baseline using participants’ height in meters and 
weight in kilograms. 
 
CD4 count was measured at study entry and at weeks 4, 8, and every eight weeks 
thereafter through week 96. Levels of nutritional and inflammatory markers were 
measured at baseline; all biomarker levels were measured at ACTG laboratories that were 
externally assured as part of the NIH Division of AIDS and ACTG Network lab quality 
assurance [21].  
 
Micronutrient concentrations were measured at a CLIA-certified laboratory at the Johns 
Hopkins Hospital (Baltimore, MD). Vitamin B12 was measured using Abbott AxSYM 
(Abbott Canada, Quebec, Canada), and vitamin B6 levels were measured by high 
performance liquid chromatography-fluorescence detection (HPLC-FD). All antioxidants 
and fat-soluble vitamins (vitamin A, α-tocopherol, γ-tocopherol, α-carotene, β-carotene, 
7 
 
β-cryptoxanthin, lutein, zeaxanthin, and lycopene) were measured using high 
performance liquid chromatography-ultraviolet detection (HPLC-UV). Serum 25(OH)-
vitamin D levels were using a chemiluminescence immunoassay (DiaSorin, Stillwater, 
MN), which reports a total serum 25(OH)-vitamin D concentration. Selenium 
concentration was measured using a Perkin-Elmer AAnalyst 600 graphite furnace atomic 
absorption spectrometer. Ferritin was measured using the Alpco Ferritin ELISA kit 
(ALPCO Diagnostics, Salem, NH), and soluble transferrin receptor and C-reactive 
protein (CRP) were measured using the Quantikine ELISA kit (R&D Systems, 
Minneapolis, MN).   
 
Inflammatory markers other than CRP were measured at the University of California, 
Davis School of Medicine (Davis, CA). LPS was measured using the Limulus 
Amebocyte Lysate assay (Lonza, Walkersville, MD), and soluble CD14 and endocab 
IgM were measured using ELISA assays (R&D Systems, Minneapolis, MN; Hycult 
Biotechnology, Plymouth Meeting, PA). Interferon-γ, TNF-α, and IL-6 were measured 
using the MILLIPLEX MAP Human High Sensitivity Cytokine/Chemokine Multiplex 
Assay (Millipore, Billerica, MA), and IP-10 was measured with the Human IP-10 V-
PLEX Kit (Meso Scale Discovery, Rockville, MD). 
 
Variable definitions and coding for analysis 
Vitamin B12 and soluble transferrin receptor values were converted into SI units before 
analysis [22]. Deficiency measures for nutritional biomarkers were defined in accordance 
with prior publications and clinically relevant standards. Vitamin B12 deficiency was 
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defined as <148 pmol/L; vitamin B6 deficiency was defined as <19 nmol/L; vitamin A 
deficiency was defined as <0.7 umol/L; ferritin deficiency was defined as <12 ug/L; 
soluble transferrin receptor deficiency was defined as >8.3 mg/L; and selenium 
deficiency was defined by serum selenium levels of <85 ug/L [23][24]. Deficiency 
measures for soluble transferrin receptor-ferritin index (>1.8) indicate iron deficiency 
[25]. 25(OH)-vitamin D deficiency was defined as <32 ng/ml, with further categories of 
insufficiency (20-32 ng/ml), moderate deficiency (10-<20 ng/ml), and severe deficiency 
(<10 ng/ml), as seen in previous publications [26]. However, because there were no 
significant differences between the levels of deficiency we used 25(OH)-vitamin D as a 
dichotomous variable with a threshold of 32 ng/ml. LPS levels were considered elevated 
if LPS could be detected in the serum sample; otherwise if no LPS was detectable in the 
sample, LPS was considered within a normal range. Although there is an accepted 
deficiency measure for α-tocopherol (<9.3 μmol/L), only one individual was deficient (in 
Malawi); thus, we analyzed α-tocopherol in quartiles as described below. 
 
For all biomarkers without defined levels of deficiency, including all immune activation 
markers except LPS, quartiles were used to analyze the effect of baseline levels on CD4 
reconstitution. Nutritional biomarkers were analyzed using the highest quartile (Q4) of 
baseline biomarker as a reference, and results are presented in order of decreasing 
quartile, with Q1 containing the lowest values for each biomarker (the most deficient 
samples). Inflammatory markers and plasma cytokines used the lowest quartile (Q1) as a 
reference since elevated levels of these biomarkers have been seen to be associated with 
disease progression [27][28]. Cutoffs for quartiles for each variable can be seen in 
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Appendix B, and Lowess plots measuring the CD4 recovery by demographic variables 
and biomarkers can be found in Appendices C and D, respectively.  
 
A variable for BMI was calculated using each participant’s weight and height at baseline 
using the formula: BMI = weight (kg) / height
2
 (m). In the analysis, we used BMI as a 
categorical variable in accordance with the WHO International Classification system. A 
BMI of ≤18.5 is categorized as underweight; a BMI of >18.5 and ≤25 is considered 
within the normal BMI range; and a BMI >25 is categorized as overweight [29]. Ninety-
six individuals had BMI>25; because most of those individuals were not considered 
obese by WHO standards (BMI>30), we did not further categorize the data into 
overweight and obese categories.  
 
Age was used as a dichotomous variable, with a cutoff point of 40 years based on the 
literature discussing the impact of age on CD4 count and HIV progression [30]. Race was 
coded in four non-overlapping categories: white, black, Hispanic, and Asian. One 
individual from the United States who identified as more than one race was dropped from 
the analysis. Demographic risk factors for established nutritional deficiencies were 
assessed using Fisher’s exact test, and baseline biological risk factors were assessed using 
a t-test for means stratified by nutritional deficiency. 
 
Longitudinal Data Analyses 
First, the effect of baseline levels of biomarkers on CD4 recovery was assessed using a 
random-effects generalized least squares (GLS) linear model. In order to assess early and 
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late effects of biomarkers, the outcome variable was the absolute change in CD4 count at 
24 (“early’) and 96 weeks (“late”), measured continuously. The GLS random-effect 
model was used to fit regression models to panel data while allowing for subject-specific 
effects, and modeled the change in the outcome variable (i.e, continuous CD4 count) in 
relation to other covariates. As previously described, in our analysis we used biological 
thresholds for biomarkers with accepted deficiency levels and quartiles for biomarkers 
without accepted deficiency measures. Covariates were included in the adjusted models if 
they were found to be significant on univariate analysis (p<0.05) or known to be 
associated from previous studies (shown in Appendix A). Missing data was managed 
using model-wise deletion.  
 
An additional logistic regression analysis was conducted to observe the association 
between established nutritional deficiencies and CD4 recovery. In the regression models, 
CD4 recovery was defined as an increase of ≥50 cells at 24 weeks, ≥100 cells at 48 
weeks, and ≥200 cells at 96 weeks, based on previous literature [31][32]. Recovery was 
assessed at each of these timepoints using a binary variable for recovery, and generalized 
estimating equations (GEE) with an exchangeable correlation matrix was used to 
examine the longitudinal relationship between CD4 recovery and selected nutritional 
deficiencies. This analysis was included to incorporate common thresholds for CD4 
recovery used by clinicians in order to investigate more clinically relevant changes in 
CD4 count. All analyses were conducted using STATA, version 12.1 (StataCorp LP, 





Characteristics of the study population 
The study population’s characteristics (n=469) are described in Table 1. The median age 
at study entry was 35 (IQR 29-40). The overall population was divided fairly evenly 
between the sexes, with 254 males (54.2%) and 215 females (45.8%). When considering 
country of origin, 45 individuals were from Brazil (9.6% of the population); 38 
individuals were from Haiti (8.1%); 107 individuals were from India (22.8%); 62 
individuals were from Malawi (13.2%); 36 individuals were from Peru (7.7%); 58 
individuals were from South Africa (12.4%); 37 individuals were from Thailand (7.9%); 
48 individuals were from the United States (10.2%); and 38 individuals were from 
Zimbabwe (8.1%).  5.5% were white non-Hispanic, 47.3% were black non-Hispanic, 
16.0% were Hispanic, and 31.1% were Asian. The majority (67.2%) fell within the 
normal BMI range, with 58 individuals (12.4%) categorized as underweight and 90 
individuals (20.5%) categorized as overweight or obese. Almost one-fourth (23.9%) had 
TB disease at baseline. Mean (SD) baseline hemoglobin levels were 12.1 g/dl (1.99 g/dl). 
The average CD4 count at baseline was 153.2 (SD 84.6) cells/mm
3
, and the average viral 
load at baseline was 218192.6 (SD 229007.9) copies/mL. The individuals included in our 
study population that were outside of the random subcohort were not found to be 
significantly different than the comparable individuals in the random subcohort based on 




Prevalence of nutrient deficiencies in HIV-infected adults 
Baseline serum samples from the full cohort of ART-naïve HIV-infected individuals 
(n=469) were tested for concentrations of vitamin A, vitamin B12, vitamin B6, 25(OH)-
vitamin D, vitamin E (α-tocopherol and γ-tocopherol), soluble transferrin receptor, 
selenium, α-carotene, β-carotene, β-cryptoxanthin, lutein, zeaxanthin, and lycopene. 
Approximately 12% of the samples for each biomarker were not able to be tested due to 
low plasma volume or regulatory complications with exporting samples from India; these 
missing samples were excluded from the analysis. We measured prevalence of nutrient 
deficiencies in the cohort among those nutrients with accepted deficiency measures. Of 
the study population, 7.3% were deficient in vitamin B12 (n=397); 37.1% were deficient 
in vitamin B6 (n=372); 3.9% were deficient in vitamin A (n=411); 53.9% were deficient 
or insufficient in 25(OH)-vitamin D (n=410); 9.3% were considered iron depleted based 
on the soluble transferrin receptor-ferritin index (n=408); and 58.3% were deficient in 
selenium (n=412) (Table 2).  
 
Demographic risk factors for nutritional deficiency 
Risk for established nutritional deficiencies was assessed by demographic and biological 
factors included in the regression models (race/ethnicity, BMI category, sex, age, 
tuberculosis disease, hemoglobin level and viral load measured at baseline; results shown 
in Table 3). For vitamin B6, white race was significantly associated with deficiency 
(p=0.014). Vitamin A deficiency was associated with lower mean hemoglobin (difference 
of 2.85 g/dl; p<0.001). 25(OH)-vitamin D deficiency was significantly associated with 
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Asian ethnicity (p<0.001) and overweight BMI category (p=0.042). Selenium deficiency 
was associated with black race (p<0.001), underweight BMI category (0.042), female sex 
(p=0.012), age under 40 (p=0.024), TB disease (p=0.002), lower mean hemoglobin levels 
(difference of 0.69 g/dl; p<0.001), and lower mean baseline CD4 count (difference of 
17.7 cells/mm
3
; p=0.04) . High soluble transferrin – ferritin index (indicative of iron 
deficiency) was significantly associated with overweight BMI category (p=0.005), female 
sex (p<0.001), lack of TB disease (p=0.047), higher mean baseline CD4 count (difference 
of 43.6 cells/mm
3
; p=0.003), lower mean hemoglobin levels (difference of 1.06 g/dl; 
p=0.002), and lower mean viral load (difference of 125542 copies/mL; p=0.002). 
 
Linear Analysis of Biomarkers at Week 24 
Significant differences were found in CD4 recovery at 24 weeks based on baseline 
nutritional (Tables 4a, 4b) and inflammatory (Tables 5a, 5b) biomarkers. Univariate 
analysis (Model A) on nutritional biomarkers revealed statistically significant 
associations by α-carotene, β-carotene, zeaxanthin, ferritin, the soluble transferrin 
receptor-ferritin index, and selenium; the inflammatory biomarkers CRP, interferon- γ, 
IL-6, and IP-10 were also significantly associated in the univariate model. When adjusted 
for baseline CD4 count (Model B), only zeaxanthin, 25(OH)-vitamin D, and sCD14 were 
significantly associated with CD4 recovery. After adjustment for race, sex, age, BMI 
category, treatment regimen, presence of TB at baseline, viral load at baseline, and 
baseline hemoglobin levels (Model C), α-carotene, β-carotene, β-cryptoxanthin, 
zeaxanthin, lycopene, 25(OH)-vitamin D, ferritin, the soluble transferrin receptor-ferritin 
index, selenium, and IL-6 were significantly associated with CD4 recovery. In the full 
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combined model, Model D (adjusting for race, sex, age, BMI category, treatment 
regimen, presence of TB at baseline, viral load at baseline, baseline hemoglobin levels, 
and baseline CD4 count), significant associations were found between CD4 recovery and 
low levels of β-carotene (decrease of 21CD4 cells, 95% CI: 40, 2); low levels of lycopene 
(decrease of 20 CD4 cells, 95% CI: 39, 2); and 25(OH)-vitamin D deficiency (decrease of 
14 CD4 cells, 95% CI: 27, 2). 
 
Linear Analysis of Biomarkers at Week 96 
At 96 weeks, we observed similar significant associations between the nutritional (Tables 
6a, 6b) and inflammatory (Tables 7a, 7b) biomarkers measured at baseline and the CD4 
recovery. Univariate analysis (Model A) revealed statistically significant associations 
between CD4 recovery and baseline vitamin B12, α-carotene, β-carotene, ferritin, 
selenium, CRP, and IL-6. When further adjusted for baseline CD4 (Model B), only α-
carotene and selenium retained statistically significant associations with overall CD4 
recovery. Adjustment for demographic variables only (Model C) revealed significant 
associations with α-carotene, β-carotene, zeaxanthin, lycopene, 25(OH)-vitamin D, 
selenium, and IL-6. When using the fully adjusted model (Model D), we observed 
significant associations between CD4 recovery and lower levels of α-carotene (decrease 
of 40 CD4 cells, 95% CI: 66, 14); low levels of lycopene (decrease of 28 CD4 cells, 95% 
CI: 56, 1); selenium deficiency (decrease of 24 CD4 cells, 95% CI: 43, 5); and slightly 
increased values of soluble CD14 (for quartiles 2 and 3, respectively: increases of 31 
CD4 cells, 95% CI: 6, 57 and 31 CD4 cells, 95% CI: 5, 56). We also observed that 
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25(OH)-vitamin D deficiency was trending significant as well (decrease of 18 CD4 cells) 
with a p-value of 0.059. 
 
Logistic Analysis of Biomarkers at Week 96 
Using the recovery standards previously described, we conducted logistic regression to 
determine which of the recognized nutritional deficiencies were more likely to affect 
CD4 recovery at 96 weeks, using the models previously defined for the GLS analyses 
(Table 8). In all models, vitamin B12 deficiency was associated with a higher odds of  
CD4 non-recovery; in Model D, this association was significant with a p-value of 0.031 
(OR=2.00, 95% CI: 1.07, 3.73). Selenium deficiency was also significantly associated 
with worse CD4 recovery in the fully adjusted model, with a p-value of 0.024 (OR=1.54, 
95% CI: 1.06, 2.24). 
 
DISCUSSION 
In this analysis we observed micronutrient deficiencies that significantly impacted CD4 
recovery to 24 and 96 weeks. In our fully adjusted linear model, selenium deficiency and 
25(OH)-vitamin D deficiency were both associated with a poorer CD4 recovery, with 
decreases at 96 weeks of 24 cells/mm
3
 and 18 cells/mm
3
, respectively (compared to a 
non-deficient individual). Lower levels of α-carotene and lycopene were also associated 
with decreases of 40 cells/mm
3
 and 28 cells/mm
3
, respectively, at 96 weeks. Our data 
suggest that baseline nutritional factors, specifically micronutrient status, influence long-
term CD4 recovery. Vitamin D, selenium, and carotenoids (including α-carotene, β-
carotene, β-cryptoxanthin, zeaxanthin, lutein, and lycopene) all have antioxidant 
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properties, and have previously been linked with the inactivation of nuclear factor Kappa 
B (NF-κB), which plays an important role in the activation of HIV [33]. 
 
WHO has long recognized nutrition as an important factor in HIV progression; in its 
2003 report on nutritional requirements for people living with HIV/AIDS (PLWH), the 
impact of nutritional deficiencies on disease progression is explored and further research 
on this topic is requested [34]. In order to better understand the effect of micronutrients 
on HIV progression and mortality, recent clinical trials have observed the effect of 
different types of micronutrient supplementation in HIV-positive individuals 
[35][36][37][38]. These studies have typically been conducted in a single country and 
either looking at a single micronutrient such as zinc [38] or a multivitamin supplement 
which typically includes Vitamins B, C, and E; niacin; and folic acid [35][36][37]. 
Unsurprisingly, no prospective randomized trials have investigated the effect of 
micronutrient deficiencies without supplementation in the context of a global cohort that 
includes both resource-limited and resource-adequate settings [39]. 
 
Although micronutrient deficiencies are very common in HIV-infected individuals, the 
literature on nutritional deficiencies and longitudinal CD4
 
recovery is relatively limited. 
Few markers have been independently associated with HIV progression; however, 
selenium is clearly implicated as having a role in the process [42]. Selenium, like many 
other micronutrients, has immunomodulatory functions; an irregularity in selenium level 
may affect a host’s susceptibility to infection and the subsequent immune response [43]. 
Observational studies thus far have been inconclusive but tend to associate lower serum 
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selenium levels with a higher risk for mortality and opportunistic infections in HIV-
infected individuals [44][45]. In the randomized trials that have been conducted thus far, 
selenium supplementation has also been associated with decreased rate of HIV 
progression and rates of hospitalization [46][47]. In a 2007 randomized trial conducted 
by Hurwitz, et al., selenium supplementation was associated with decreased viral load; in 
a follow-up analysis based on serum selenium levels, high serum selenium was 
associated with an increase in CD4 count [48]. Results of another randomized trial 
published in 2013 found that selenium supplementation combined with multivitamin 
supplementation resulted in a lower risk of significantly decreased CD4 count, AIDS-
defining conditions, or AIDS-related death in an asymptomatic ART-naïve cohort of 
adults [49]. Selenium deficiency has also been associated with a higher risk of mortality 
from HIV in a cohort of treatment-naïve adults from the United States [24]. However, as 
of yet there is little information on how selenium deficiency impacts CD4 recovery. 
 
Our findings in regards to selenium, which demonstrate a difference in CD4 recovery 
based on selenium status, are consistent with our expectations based on the findings from 
previous observational cohorts and randomized trials. Studies in intravenous drug users 
including patients both on ART and not on ART have shown that low levels of selenium 
are associated with HIV-related mortality [24], development of mycobacterial diseases 
such as tuberculosis [63], and co-infection with HCV [64], all of which have been 
previously associated with CD4 count. The observational study of pregnant women not 
on ART in Tanzania showed a positive association between plasma selenium levels and 
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CD4 count in the first year of follow-up; although our study included only patients on 
ART, we saw the same relationships [44].  
 
Supplementation with selenium has also been seen to improve outcomes of patients with 
HIV, including a reduced viral load, indirect improvement of CD4 count, and reduced 
hospitalizations [46][48]. There are many proposed biological mechanisms related to 
selenium deficiency in HIV-infected individuals; while this relationship is complicated 
and multifactorial, the most widely-accepted are gastrointestinal malabsorption of 
selenium and deficient dietary intake [65][66]. Selenium may not be as well absorbed 
during the normal digestion process, which can lead to lower levels of selenium entering 
the bloodstream. While the relationship is not confirmed due to lack of adequate 
statistical studies, there does seem to be a relationship between selenium uptake in the 
gastrointestinal tract and HIV infection independent of gastrointestinal issues such as 
diarrhea, bowel pathogens, or general gastrointestinal malabsorption [65]. Selenium 
deficiency can also lead to impaired immune function, but supplementation has shown to 
restore immune activity in deficient individuals [49]. It is likely that the antiviral and 
antioxidant properties of selenium seen in vitro have an effect on HIV; due to these 
properties, when an individual is deficient in selenium HIV will actively replicate at a 
higher rate, thus destroying more CD4 cells and causing a lowered CD4 recovery 
compared to a non-deficient individual [23]. 
 
Deficiency of 25(OH)-vitamin D, has also been shown to affect HIV progression in 
treatment-naïve patients. In the ANRA-C09-COPANA cohort, a prospective study of 
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newly diagnosed HIV-1 infected individuals being conducted in 37 hospitals in France, 
patients classified as 25(OH)-vitamin D deficient at baseline were also more likely to 
have a CD4 count of  <100 cells/mm
3
 [50]. However, this association was reduced once 
the analysis was adjusted for inflammatory markers such as hsCRP, sTNFR1, and 
sTNFR2; this implies that the association can be partly attributed to the actions of these 
inflammatory markers [50]. A similar finding was also replicated in a study from the 
Women’s Interagency HIV Study (WIHS); HIV-positive women who were 25(OH)-
vitamin D insufficient or deficient were more likely to have a diminished CD4 recovery 
after HAART initiation to 24 months [51]. In another prospective study, 25(OH)-vitamin 
D was found to be positively associated with improved immune restoration after initiating 
ART [52].   
 
However, the evidence for the association of 25(OH)-vitamin D and CD4 recovery is not 
as strong from a supplementation standpoint. A 2011 study conducted in HIV-infected 
children in Toronto (75% of whom were 25(OH)-vitamin D insufficient or deficient) 
observed no increase in CD4 count compared to a placebo after a six-month regimen of 
high-level 25(OH)-vitamin D supplementation [53]. Despite the high prevalence of 
25(OH)-vitamin D deficiency in HIV-infected adults, the exact relationship between 
25(OH)-vitamin D and CD4 recovery remains unclear [54].  
 
Our analysis found that baseline 25(OH)-vitamin D levels are associated with worse 
long-term CD4 recovery, which is generally supported by the literature; both cross-
sectional and supplementation studies indicate that a deficiency of 25(OH)-vitamin D 
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among HIV-infected individuals can lead to more adverse outcomes such as  mortality 
and progression to AIDS [67]. However, one study of 25(OH)-vitamin D 
supplementation in children showed no increase in CD4 cell count with a high level of 
25(OH)-vitamin D supplementation, and not all of the treated children even reached 
sufficiency [53]. While we did not see a similar relationship in this study, the children in 
the supplementation study entered with relatively high CD4 counts (mean of 927 
cells/mm
2
) compared to our study population, which only included individuals with a 
CD4 count of less than 350 cells/mm
3
 at baseline [53]. However, this raises an interesting 
point – if 25(OH)-vitamin D supplementation is not very effective in boosting CD4 
recovery for individuals found to be deficient before ART initiation, should we test at all? 
The potential benefits need to be explored and weighed with the cost and difficulty of 
these tests in order to make decisions that will have a meaningful impact for patients. 
More research is needed to determine the specific effect of 25(OH)-vitamin D deficiency 
on CD4 recovery after initiation of ART.  
 
Iron status has also been implicated in the progression of HIV, although the literature 
thus far has been inconclusive. It has been proposed that high iron stores may have an 
adverse effect on immunity and the function of the immune system; retrospective studies 
in the serum and bone marrow have observed that the rate of HIV progression was 
significantly faster in patients with higher iron status (measured by serum ferritin 
concentration and iron stores in bone marrow aspirations) [55]. However, other studies in 
both adults and children have indicated that iron-deficiency anemia independently 
predicts adverse outcomes such as more severe clinical presentation and more severe 
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immunosuppression [56][57][58][59]. Yet other studies have found that iron stores 
measured by serum levels of soluble transferrin receptor and ferritin are not related to 
HIV progression, although they are indicative of anemia [60]. Additionally, the 
relationship between HIV progression and iron status is complicated by the fact that iron 
status is also associated with common HIV co-morbidities such as tuberculosis and 
malaria [61][62]. Our findings show a moderately strong relationship between iron 
deficiency and CD4 count at week 24 in the GLS models when measured by the soluble 
transferrin receptor – ferritin index (CD4 count decreases by approximately 40 
cells/mm
3
), although the relationship becomes non-significant when the model is adjusted 
for baseline CD4 count. While this is the general relationship we were expecting to see, 
further investigation is necessary to determine how baseline CD4 count and iron stores 
and use are associated in the context of HIV infection. 
 
In our findings we also saw relationships between CD4 recovery and carotenoids, most 
notably the association observed between CD4 recovery and levels of β-carotene. 
Carotenoids (including α-carotene, β-carotene, β-cryptoxanthin, zeaxanthin, lutein, and 
lycopene) have antioxidant properties and lower levels of carotenoids have been 
associated with higher rates of HIV seroconversion and HIV-related symptoms [70][71]. 
In our study, low levels of β-carotene were significantly associated with worse CD4 
recovery at both 24 weeks and 96 weeks in the GLS models. Previously, β-carotene has 
been seen in lower levels in treatment-naïve HIV-infected children than in HIV-
uninfected children, which was hypothesized to be a consequence of β-carotene’s 
elimination of free radicals under normal conditions [71]. When an individual is deficient 
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in β-carotene, free radicals are able to enhance the activation of NF-κB, which is known 
to promote HIV replication [71]. Because these deficiencies can allow for greater 
activation and replication of HIV, more viruses are able to infect and destroy CD4 cells, 
thus leading to a decrease in CD4 cells as the disease progresses. Thus, it is not surprising 
that most micronutrient supplementation studies include carotenoids (most commonly, α-
carotene and β-carotene) in supplementation regimens. In countries like South Africa, 
where we observed that approximately one-third of the study population was in the 
lowest quartile of β-carotene levels, it may be feasible to start all treatment naïve HIV 
patients on a micronutrient supplementation regimen that includes β-carotene as a way to 
boost immune function and prevent further adverse events. 
 
Vitamin B12 was also strongly implicated in the logistic regression, although only to a 
small extent in the GLS analysis. In all GEE models, vitamin B12 deficiency essentially 
doubled the odds of not achieving CD4 recovery by 96 weeks based on the thresholds at 
24, 48, and 96 weeks. Previously, an association has been seen between low levels of 
vitamin B12 and HIV disease; it has been seen in multiple countries that vitamin B12 
levels are generally lower in HIV patients [72][73]. Similar to  β-carotene, malabsorption 
is thought to be a mechanism through which vitamin B12 deficiency is mediated through 
HIV infection [74][75]. One retrospective study in Uganda found that sub-optimal levels 
of vitamin B12 were associated with a longer known duration of HIV infection and higher 
rate of CD4 decline pre-ART; the authors suspect that the observed deficiency was due to 
an increased demand to replace CD4 cells depleted by HIV, although they did not have 
data to support that theory [73]. Supplementation studies have likewise shown little about 
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the effects of vitamin B12 alone – because many supplementation studies include vitamin 
B12 as part of a complex with vitamin B6 or as part of a multivitamin with many 
components, it is difficult to parse out the independent effect of vitamin B12 on HIV-
related outcomes. More investigation with prospective and molecular studies are needed 
in order to better understand this relationship. 
 
Inflammatory and immune activation biomarkers have also been associated with HIV and 
disease progression, as an increase in these markers signals that the immune system is 
taking action against the virus. However, the exact biological role of these markers in 
HIV infection and CD4 recovery is not known. Previous studies have shown that 
increased plasma levels of sCD14, a marker of monocyte activation, were associated with 
two markers of HIV disease progression, hsCRP and D-dimer [40]. Increased levels of 
sCD14 are also the only known strong independent predictor of mortality in HIV-infected 
individuals among immune activation markers [27][41]. In our study, sCD14 was the 
only immune activation or inflammatory marker found to be significantly associated with 
CD4 recovery in the linear models; however, at 96 weeks, moderately increased levels 
(quartiles 2 and 3) of sCD14 were associated with a higher CD4 count compared to the 
lowest quartile. No other studies have investigated this relationship, so it is possible that 
sCD14 is working to increase markers of HIV progression via a pathway other than CD4 
cells. More investigation is needed to more fully understand this relationship and how 





We also observed an interesting result in the demographics of the groups who were 
deficient in nutritional biomarkers. Because most of the deficiencies measured here had 
unique demographic risk factors (including sex, age, country, race, BMI category, and 
TB at baseline), it is difficult to create a risk factor profile that is applicable across 
nutrients and locations. We were not able to observe any demographic risk factor that 
was a risk factor for deficiency across all nutrients; there was even very little consistency 
in deficiencies across countries. For instance, Brazil, which generally ranked low to 
average among deficient countries, had the highest rate of selenium deficiency – a 
micronutrient for which low levels were seen in Haiti and the United States.  Because 
there are such great differences in risk factors for each micronutrient and between the 
countries, it is imperative that researchers and clinicians understand the context in which 
they are working, and look for these risk factors on a more local level.  
 
An important consideration for this cohort was finding an appropriate time point at which 
to look for associations between biomarkers and CD4 recovery. In the past, it has been 
shown that other markers such as weight were relatively reliable indicators of individuals 
at high risk for adverse outcomes at times as early as one month after treatment initiation; 
however, because our primary outcome was CD4 recovery, we had to take into account 
the biological processes occurring surrounding CD4 cells after treatment initiation [68]. 
In approximately the first eight weeks after treatment initiation, the increase in circulating 
CD4 cells can be attributed mainly to migration of the CD4 cells from the lymphoid 
tissues to blood [69]. Because these cells are not newly-created lymphocytes, this initial 
short-term (8-12 weeks) increase seen in the blood is not necessarily indicative of the 
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revival of either short- or long-term immune response due to treatment. In fact, the 
intensity of this initial recovery in CD4 cells is closely associated with the overall relative 
depletion of CD4 cells at the time of treatment initiation, as well as the slope of the CD4 
decline in the year prior to treatment [69]. Because of this lag in indication of CD4 cells 
in blood, we chose to use 24 weeks as a marker of our short-term CD4 recovery. In this 
study, CD4 counts and other data were collected until week 96, which is the timepoint we 
used to observe long-term CD4 recovery; however, recovery is typically observed 
clinically over five or more years in order to preclude immunologic failure [20]. Yet we 
saw many of the same associations between CD4 recovery and biomarkers in both the 
short- and long-term analyses; this may indicate that once treatment is initiated, there is 
little change in trajectory over time.  
 
These findings have several limitations. For cost and logistic reasons, measurement of the 
biomarkers in the PEARLS cohort was only undertaken for a smaller cohort of 
participants instead of the full study cohort, and we could not include the numerous 
individuals in the analysis for which there was no data. There were also very few cases of 
immunologic failure in the entire cohort (n=14), which affected our ability to investigate 
factors associated with immunologic failure. This may indicate that our cohort is 
generally healthier than the population of individuals starting ART treatment in these 
countries, which may bias our study and limit the generalizability of our results. For 
micronutrients in which only a small percentage of the population was considered 
deficient (such as vitamin B12), it was difficult to see an effect on CD4 recovery with 
such a small sample size, which may be contributing to the lack of effect we observed. 
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Missing data is also an issue for some of the samples (specifically from India), as there 
were delays in processing and customs that caused the samples to be lost; this has the 
potential to affect our conclusions if the participants in India were different than the 
participants in the rest of the cohort. 
 
Despite these limitations, this analysis demonstrates the global importance of 
micronutrient deficiencies on HIV progression and CD4 recovery in treatment-naïve 
patients. Although there was a large amount of heterogeneity in the cohort due to the nine 
study locations, the findings were still discriminatory; this lends power to the study and 
validates the findings on a global scale. With participants in nine low-, intermediate-, and 
high-income countries on four continents, this is a unique and globally representative 
cohort. Standardization of study protocols, enrollment procedures and criteria, lab 
analysis techniques, and quality assurance/control measures ensured that the data was of 
high quality and consistent across study sites. Moving forward with this research, we 
should continue to focus on comprehensive high-quality data collection in a diverse 
global context.  
 
In conclusion, lower baseline levels of micronutrients (specifically, selenium and 
25(OH)-vitamin D) in HIV-infected patients at ART initiation are associated with worse 
CD4 recovery in both the short- and the long-term. These findings suggest that in the 
future, baseline levels of these micronutrients could be a valuable tool for clinical 
decision-making and providing supplementary treatment for HIV-infected patients who 












18.5 - 25 315 (67.2)
>25 96 (20.5)














South Africa 58 (12.4)
Thailand 37 (7.9)
United States 48 (10.2)
Zimbabwe 38 (8.1)
TB at baseline 112 (23.4)
Hgb at baseline (g/dl)* 12.1 (2.0)
VL at baseline (cells/mL)† 218192.6  (229007.9)
† 468 individuals included in analysis due to missing samples
Table 1. Characteristics of the study population 
(n=469)
Data are presented as n (%) unless otherwise specified. P-values were calculated from    t-
tests and Fisher's exact test for continous and categorical variables, respectively






Vitamin B12                                             
(n = 397)
Vitamin B6                                              
(n = 372)
Vitamin A       
(n = 411)
25(OH)-vitamin D        
(n = 410)




Index  (n = 408)
Brazil 3 (6.7) 18 (40.9) 0 (0) 12 (26.7) 41 (91.1) 1 (2.2)
Haiti 5 (13.5) 13 (35.1) 2 (5.4) 12 (32.4) 2 (5.4) 2 (5.4)
India 4 (6.7) 12 (21.8) 1 (1.6) 45 (72.6) 28 (45.2) 2 (3.2)
Malawi 0 (0) 27 (48.2) 6 (9.8) 24 (40.7) 57 (93.4) 10 (17.0)
Peru 3 (8.6) 10 (50.0) 1 (2.9) 15 (42.9) 12 (34.3) 3 (8.9)
South Africa 2 (4.3) 15 (30.0) 2 (3.7) 32 (58.2) 48 (87.3) 7 (13.0)
Thailand 4 (12.9) 7 (26.9) 0 (0) 24 (75.0) 14 (43.8) 3 (9.4)
United States 1 (2.3) 19 (40.4) 0 (0) 38 (79.2) 1 (2.1) 6 (12.5)
Zimbabwe 7 (18.9) 17 (46.0) 4 (10.8) 19 (51.4) 37 (100) 4 (11.1)
TOTAL 29 (7.3) 138 (37.1) 16 (3.9) 221 (53.9) 240 (58.3) 38 (9.3)
Data presented as No. (% deficiency by country)













Deficiency                                            
(n = 29)
Vitamin B6 
Deficiency                                             
(n = 138)
Vitamin A            
Deficiency                   
(n = 16)
25(OH)-vitamin D 
Deficiency                     
(n = 221)
Selenium 




Index Deficiency              
(n = 38)
Gender
Male 20 (9.4) 73 (37.1) 5 (2.2) 117 (52.0) 119 (52.3) 7 (3.1)
Female 9 (4.9) 65 (37.1) 11 (5.9) 104 (56.2) 121 (65.1)* 31 (17.0)*
Age
<40 15 (5.5) 88 (35.8) 11 (3.9) 151 (53.9) 174 (62.1)* 25 (9.1)




<18.5 0 (0) 17 (40.5) 3 (6.7) 26 (57.8) 31 (68.9)* 4 (8.9)
18.5 - 25 21 (7.8) 91 (36.6) 12 (4.3) 138 (49.8) 167 (59.9) 18 (6.5)
>25 8 (9.4) 30 (37.0) 1 (1.1) 57 (64.8)* 42 (47.7) 16 (18.8)*
Race
White 1 (4) 12 (46.2)* 0 (0) 12 (46.2) 15 (57.7) 0 (0)
Black 14 (6.8) 86 (42.0) 14 (6.5) 110 (51.4) 148 (68.5)* 27 (12.7)*
Hispanic 6 (8.1) 21 (36.2) 1 (1.4) 28 (37.8) 34 (46.0) 6 (8.1)
Asian 8 (8.6) 19 (22.9) 1 (1.0) 71 (74.0)** 43 (44.8) 5 (5.2)
TB at Screening
No TB 21 (6.9) 109 (38.7) 12 (3.8) 166 (52.9) 171 (54.1) 34 (10.9)*
TB 8 (8.7) 29 (32.2) 4 (4.2) 55 (57.3) 69 (71.9)* 4 (4.2)
Mean difference in 




20.76 14.6 4.43 0.27 17.7* -43.6*
Mean difference in 
Hgb at Screening 
(g/dl)†
-0.07 0.3 2.9** 0.22 0.69** 1.06**
Mean difference in 
VL at Screening 
(cells/mL)†
-28481 12263 68319 36589 -29452 125542**
 P-values were calculated from t-tests and Fisher's exact test for continous and categorical variables, respectively
† Mean difference = (mean in non-deficient individuals) - (mean in deficient individuals)
* p<0.5; ** p<0.001
Table 3. Baseline demographic and biological risk factors for nutritional deficiencies






Biomarker Coefficient P-value 95% CI Coefficient P-value 95% CI
α-tocopherol
Q3 10.59 0.494 [-19.76, 40.94] 0.38 0.967 [-17.47, 18.22]
Q2 16.62 0.283 [-13.73, 46.98] -9.59 0.295 [-27.54, 8.36]
Q1 6.42 0.679 [-24.01, 36.85] -2.07 0.821 [-19.98, 15.84]
Vitamin B12 -39.47 0.065 [-81.41, 2.47] -18.07 0.151 [-42.72, 6.57]
Vitamin B6 -14.62 0.222 [-38.09, 8.86] 1.03 0.880 [-12.35, 14.41]
Retinol -0.44 0.988 [-56.12, 55.25] 4.55 0.787 [-28.39, 37.49]
γ-tocopherol
Q3 1.68 0.913 [-28.67, 32.04] -2.57 0.777 [-20.39, 15.24]
Q2 16.28 0.293 [-14.07, 46.62] 10.27 0.260 [-7.60, 28.13]
Q1 14.64 0.344 [-15.68, 44.95] 2.20 0.809 [-15.64, 20.05]
α-carotene
Q3 3.19 0.824 [-24.98, 31.36] -1.56 0.855 [-18.27, 15.16]
Q2 -27.78 0.074 [-58.23, 2.66] -9.78 0.290 [-27.88, 8.33]
Q1 -38.37 0.018 [-70.12, -6.63] -13.81 0.153 [-32.76, 5.14]
β-carotene
Q3 -30.50 0.04 [-59.54, -1.46] 4.08 0.648 [-13.45, 21.61]
Q2 -46.21 0.002 [-75.94, -16.48] -14.07 0.124 [-31.99, 3.84]
Q1 -66.02 <0.001 [-96.29, -35.74] -12.74 0.178 [-31.28, 5.80]
β-cryptoxanthin
Q3 23.89 0.117 [-5.97, 53.76] 0.62 0.946 [-17.13, 18.37]
Q2 13.83 0.354 [-15.41, 43.07] 2.26 0.799 [-15.10, 19.62]
Q1 -15.33 0.331 [-46.26, 15.60] 4.15 0.658 [-14.24, 22.54]
Lutein
Q3 8.78 0.557 [-20.54, 38.10] 2.58 0.771 [-14.76, 19.92]
Q2 12.68 0.415 [-17.78, 43.14] 14.52 0.114 [-3.47, 32.50]
Q1 -27.85 0.066 [-57.53, 1.83] 0.69 0.939 [-16.99, 18.38]
Zeaxanthin
Q3 27.11 0.046 [0.523, 53.69] 21.17 0.008 [5.48, 36.87]
Q2 2.80 0.861 [-28.41, 34.0] 17.20 0.068 [-1.27, 35.67]
Q1 -27.63 0.092 [-59.82, 4.55] 6.15 0.530 [-13.06, 25.37]
Lycopene
Q3 -18.69 0.223 [-48.73, 11.35] 1.91 0.833 [-15.86, 19.67]
Q2 -9.52 0.536 [-39.69, 20.66] 2.35 0.797 [-15.50, 20.19]
Q1 -30.94 0.047 [-61.52, -0.37] -5.70 0.539 [-23.87, 12.47]
25-OH Vitamin D -16.71 0.129 [-38.26, 4.84] -16.59 0.010 [-29.17, -4.00]
Transferrin: Ferritin 
Index
43.11 0.022 [6.27, 79.94] -2.36 0.833 [-24.34, 19.61]
Selenium -23.12 0.036 [-44.79, -1.46] -4.92 0.453 [-17.76, 7.93]
*Models are defined as follows:
     Model A: Univariate 







Table 4a. Nutritional biomarkers associated with CD4 recovery at 24 weeks (A & B)*








Biomarker Coefficient P-value 95% CI Coefficient P-value 95% CI
α-tocopherol
Q3 19.94 0.194 [-10.17, 50.04] -1.73 0.844 [-18.95, 15.48]
Q2 17.70 0.251 [-12.50, 47.90] -7.65 0.386 [-24.96, 9.66]
Q1 13.96 0.396 [-18.25, 46.18] -2.14 0.819 [-20.54, 16.25]
Vitamin B12 -27.08 0.202 [-68.63, 14.48] -16.25 0.176 [-39.77, 7.27]
Vitamin B6 -6.83 0.565 [-30.12, 16.46] 4.76 0.472 [-8.21, 17.73]
Retinol 30.18 0.295 [-26.33, 86.68] 4.23 0.798 [-28.17, 36.64]
γ-tocopherol
Q3 3.01 0.849 [-27.89, 33.91] -0.11 0.990 [-17.60, 17.37]
Q2 11.28 0.491 [-20.78, 43.34] 12.11 0.192 [-6.07, 30.29]
Q1 5.51 0.755 [-29.06, 40.08] -2.26 0.821 [-21.86, 17.34]
α-carotene
Q3 -0.43 0.976 [-28.82, 27.96] -7.63 0.356 [-23.85, 8.59]
Q2 -25.74 0.101 [-56.52, 5.05] -14.80 0.099 [-32.38, 2.78]
Q1 -33.15 0.044 [-65.48, -0.82] -17.77 0.060 [-36.30, 0.76]
β-carotene
Q3 -22.64 0.131 [-52.05, 6.77] -4.37 0.611 [-21.24, 12.49]
Q2 -34.12 0.029 [-64.80, -3.44] -17.47 0.051 [-35.04, 0.10]
Q1 -53.58 0.001 [-86.03, -21.12] -20.92 0.028 [-39.63, -2.20]
β-cryptoxanthin
Q3 31.59 0.037 [1.94, 61.24] 2.44 0.779 [-14.61, 19.49]
Q2 19.24 0.211 [-10.92, 49.39] 0.05 0.996 [-17.28, 17.38]
Q1 8.56 0.611 [-24.46, 41.58] 3.09 0.749 [-15.80, 21.98]
Lutein
Q3 7.66 0.614 [-22.07, 37.38] -6.33 0.465 [-23.30, 10.65]
Q2 19.63 0.236 [-12.81, 52.08] 7.69 0.415 [-10.79, 26.18]
Q1 -23.35 0.156 [-55.64, 8.93] -16.22 0.085 [-34.65, 2.22]
Zeaxanthin
Q3 39.05 0.004 [12.28, 65.81] 15.16 0.054 [-0.29, 30.60]
Q2 16.24 0.316 [-15.48, 47.96] 0.58 0.950 [-17.67, 18.83]
Q1 -5.44 0.751 [-39.07, 28.18] -3.70 0.708 [-23.06, 15.66]
Lycopene
Q3 -22.96 0.139 [-53.34, 7.43] -4.83 0.584 [-22.29, 30.69]
Q2 -15.95 0.318 [-47.24, 15.33] -6.62 0.467 [-24.46, 11.21]
Q1 -38.05 0.023 [-70.85, -5.25] -20.35 0.033 [-39.10, -1.60]
25-OH Vitamin D -22.78 0.042 [-44.71, -0.84] -14.07 0.027 [-26.55, -1.60]
Transferrin: Ferritin 
Index
42.24 0.030 [4.10, 80.38] 1.69 0.880 [-20.25, 23.63]
Selenium -23.80 0.036 [-46.08, -1.52] -9.18 0.158 [-21.92, 3.56]
*Models are defined as follows:
     Model C: Adjusted for race, sex, age, BMI category, treatment regimen, presence of TB at baseline,
     viral load at baseline, and baseline hemoglobin







Table 4b. Nutritional biomarkers associated with CD4 recovery at 24 weeks (C & D)*













Table 5a. Inflammatory biomarkers associated with CD4 recovery at 24 weeks (A & B)*
Biomarker Coefficient P-value 95% CI Coefficient P-value 95% CI
CRP
Q2 3.12 0.837 [-26.70, 32.94] 2.49 0.784 [-15.32, 20.29]
Q3 -35.57 0.019 [-65.38, -5.75] -7.91 0.388 [-25.86, 10.05]
Q4 -49.96 0.001 [-79.69, -20.23] -10.16 0.269 [-28.19, 7.86]
LPS -24.06 0.023 [-44.74, -3.39] -0.19 0.977 [-12.83, 12.46]
sCD14
Q2 21.95 0.162 [-8.83, 52.72] 12.55 0.171 [-5.42, 30.51]
Q3 15.94 0.311 [-14.93, 46.81] 11.27 0.221 [-6.76, 29.30]
Q4 -4.11 0.789 [-34.24, 26.02] 17.80 0.048 [-0.12, 35.49]
Endocab
Q2 3.70 0.810 [-26.51, 33.91] -0.45 0.960 [-18.23, 17.33]
Q3 1.90 0.902 [-28.27, 32.07] 3.30 0.716 [-14.44, 21.04]
Q4 1.13 0.942 [-29.07, 31.32] 1.38 0.879 [-16.38, 19.14]
Interferon-γ
Q2 -10.92 0.494 [-42.24, 20.40] 4.52 0.629 [-13.80, 22.84]
Q3 -32.29 0.044 [-63.74, -0.84] -7.33 0.437 [-25.81, 11.16]
Q4 -51.94 0.001 [-83.33, -20.54] -6.29 0.509 [-24.95, 12.38]
IL-6
Q2 -32.48 0.042 [-63.79, -1.17] -2.03 0.829 [-20.51,16.44]
Q3 -59.39 <0.001 [-90.58, -28.21] -10.16 0.285 [-28.80, 8.47]
Q4 -39.77 0.013 [-71.0, -8.54] -0.589 0.950 [-19.15, 17.97]
IP-10
Q2 -18.42 0.254 [-50.04, 13.20] -6.1 0.514 [-24.40, 12.20]
Q3 -21.43 0.186 [-53.20, 10.34] -5.61 0.550 [-24.0, 12.78]
Q4 -33.90 0.036 [-65.51, -2.27] 5.84 0.537 [-12.68, 24.35]
TNF-α
Q2 3.80 0.815 [-28.07, 33.67] 16.18 0.084 [-2.16, 34.51]
Q3 1.37 0.933 [-30.58, 33.32] 8.38 0.371 [-9.99, 26.76]
Q4 -12.28 0.450 [-44.15, 19.59] 14.32 0.128 [-4.12, 32.76]
*Models are defined as follows:
     Model A: Univariate 



















Table 5b. Inflammatory biomarkers associated with CD4 recovery at 24 weeks (C & D)*
Biomarker Coefficient P-value 95% CI Coefficient P-value 95% CI
CRP
Q2 6.14 0.684 [-23.44, 35.72] 0.792 0.927 [-16.06, 17.64]
Q3 -18.47 0.231 [-48.70, 11.76] -5.88 0.505 [-23.17, 11.41]
Q4 -26.18 0.104 [-57.71, 5.34] -12.33 0.180 [-30.33, 5.68]
LPS -17.43 0.104 [-38.46, 3.61] 6.78 0.283 [-5.60, 19.13]
sCD14
Q2 14.65 0.342 [-15.58, 44.88] 16.88 0.052 [-0.178, 33.94]
Q3 13.32 0.396 [-17.43, 44.06] 13.65 0.123 [-3.71, 31.02]
Q4 6.62 0.676 [-24.43, 37.68] 14.04 0.118 [-3.55, 31.64]
Endocab
Q2 -5.97 0.695 [-35.81, 23.86] -4.42 0.611 [-21.42, 12.59]
Q3 -0.21 0.989 [-29.96, 29.54] -0.23 0.978 [-17.15, 16.68]
Q4 -0.72 0.963 [-30.76, 29.32] -5.81 0.506 [-22.91, 11.30]
Interferon-γ
Q2 -5.23 0.744 [-36.60, 26.14] 2.47 0.783 [-15.09, 20.02]
Q3 -24.33 0.129 [-55.73, 7.07] -10.74 0.232 [-28.36, 6.88]
Q4 -39.38 0.014 [-70.64, -8.13] -6.75 0.454 [-24.42, 10.91]
IL-6
Q2 -25.43 0.112 [-56.74, 5.89] -6.61 0.461 [-24.20, 10.98]
Q3 -51.36 0.001 [-83.03, -19.68] -16.97 0.063 [-34.89, 0.95]
Q4 -28.14 0.079 [-59.54, 3.26] -4.12 0.649 [-21.82, 13.59]
IP-10
Q2 -18.18 0.254 [-49.41, 13.06] -3.21 0.718 [-20.61, 14.19]
Q3 -18.08 0.264 [-49.82, 13.67] -9.96 0.269 [-27.61, 7.70]
Q4 -26.78 0.110 [-59.62, 6.07] -13.10 0.161 [-31.43, 5.23]
TNF-α
Q2 7.38 0.647 [-24.23, 39.0] 8.97 0.317 [-8.61, 26.55]
Q3 13.77 0.398 [-18.14, 45.68] -1.25 0.890 [-19.03, 16.52]
Q4 3.38 0.841 [-29.69, 36.44] -2.83 0.763 [-21.23, 15.58]
*Models are defined as follows:
     Model C: Adjusted for race, sex, age, BMI category, treatment regimen, presence of TB at baseline,
     viral load at baseline, and baseline hemoglobin
















Biomarker Coefficient P-value 95% CI Coefficient P-value 95% CI
α-tocopherol
Q3 5.63 0.759 [-30.4, 41.66] -4.72 0.724 [-30.97, 21.53]
Q2 11.06 0.547 [-24.97, 47.09] -15.05 0.263 [-41.42, 11.33]
Q1 -9.42 0.61 [-45.58, 26.75] -17.71 0.188 [-44.09, 8.67]
Vitamin B12 -51.94 0.041 [-101.68, -2.21] -30.52 0.099 [-66.73, 5.69]
Vitamin B6 -26.36 0.063 [-54.17, 1.46] -10.66 0.294 [-30.58, 9.25]
Retinol -19.28 0.568 [-85.56, 47.0] -13.96 0.573 [-62.48, 34.56]
γ-tocopherol
Q3 5.72 0.755 [-30.28, 41.73] 1.10 0.935 [-25.15, 27.35]
Q2 16.37 0.373 [-19.67, 52.4] 9.75 0.468 [-16.57, 36.08]
Q1 26.84 0.144 [-9.15, 62.83] 14.31 0.286 [-12.0, 40.61]
α-carotene
Q3 4.24 0.803 [-29.06, 37.53] -0.73 0.953 [-25.17, 23.70]
Q2 -46.68 0.011 [-82.72, -10.64] -29.09 0.032 [-55.62, -2.56]
Q1 -40.03 0.037 [-77.62, -2.43] -15.11 0.286 [-42.87, 12.66]
β-carotene
Q3 -15.67 0.376 [-50.33, 18.99] 18.85 0.151 [-6.85, 44.56]
Q2 -47.26 0.009 [-82.76, -11.77] -15.02 0.263 [-41.32, 11.27]
Q1 -61.50 0.001 [-97.67, -25.32] -7.43 0.592 [-34.63, 19.76]
β-cryptoxanthin
Q3 17.21 0.342 [-18.26, 52.68] -6.42 0.630 [-32.52, 19.69]
Q2 2.08 0.907 [-32.65, 36.81] -9.37 0.471 [-34.88, 16.14]
Q1 -29.11 0.12 [-65.86, 7.63] -9.60 0.486 [-36.63, 17.42]
Lutein
Q3 8.14 0.648 [-26.79, 43.07] 1.78 0.891 [-23.75, 27.32]
Q2 17.06 0.356 [-19.19, 53.32] 18.96 0.160 [-7.50, 45.43]
Q1 -22.71 0.208 [-58.09, 12.67] 6.31 0.635 [-19.74, 32.35]
Zeaxanthin
Q3 23.00 0.154 [-8.61, 54.63] 16.52 0.163 [-6.71, 39.75] 
Q2 4.57 0.809 [-32.58, 41.73] 19.09 0.171 [-8.26, 46.44]
Q1 -37.98 0.052 [-76.36, 0.394] -4.24 0.771 [-32.72, 24.24]
Lycopene
Q3 -9.71 0.594 [-45.45, 26.02] 10.68 0.423 [-15.45, 36.80]
Q2 -9.25 0.614 [-45.18, 26.68] 2.44 0.855 [-23.82, 28.69]
Q1 -26.68 0.151 [-63.04, 9.71] -1.27 0.925 [-27.95, 25.41]
25-OH Vitamin D -16.44 0.208 [-42.02, 9.15] -16.29 0.086 [-34.88, 2.31]
Transferrin: Ferritin 
Index
42.98 0.054 [-0.78, 86.74] -2.50 0.880 [-34.78, 29.78]
Selenium -39.33 0.003 [-64.88, -13.77] -21.30 0.026 [-40.08, -2.51]
*Models are defined as follows:
     Model A: Univariate 







Table 6a. Nutritional biomarkers associated with CD4 recovery at 96 weeks (A & B)*









Biomarker Coefficient P-value 95% CI Coefficient P-value 95% CI
α-tocopherol
Q3 17.26 0.341 [-18.27, 52.80] -4.72 0.718 [-30.29, 20.85]
Q2 14.98 0.410 [-20.67, 50.64] -10.18 0.437 [-35.87, 15.51]
Q1 1.86 0.924 [-36.22, 39.93] -13.93 0.318 [-41.30, 13.44]
Vitamin B12 -38.19 0.125 [-87.03, 10.65] -27.53 0.121 [-62.33, 7.27]
Vitamin B6 -15.29 0.276 [-42.80, 12.22] -3.87 0.698 [-23.37, 15.64]
Retinol 34.11 0.632 [-50.52, 83.20] -8.98 0.715 [-57.12, 39.16]
γ-tocopherol
Q3 6.96 0.708 [-29.50, 43.42] 3.60 0.787 [-22.49, 29.70]
Q2 8.20 0.671 [-29.68, 46.07] 8.49 0.540 [-18.67, 35.64]
Q1 10.93 0.600 [-29.88, 51.74] 3.18 0.831 [-26.07, 32.43]
α-carotene
Q3 -4.17 0.806 [-37.45, 29.10] -11.72 0.336 [-35.61, 12.16]
Q2 -50.31 0.006 [-86.44,-14.18] -39.68 0.003 [-65.63, -13.73]
Q1 -38.52 0.047 [-76.49, -0.55] -22.80 0.102 [-50.15, 4.55]
β-carotene
Q3 -6.82 0.701 [-41.64, 27.99] 11.34 0.375 [-13.70, 36.39]
Q2 -31.66 0.088 [-67.99, 4.66] -15.13 0.256 [-41.25, 10.98]
Q1 -45.12 0.021 [-83.57, -6.68] -12.01 0.397 [-39.83, 15.80]
β-cryptoxanthin
Q3 27.57 0.123 [-7.47, 62.61] -1.81 0.889 [-27.13, 23.51]
Q2 7.07 0.697 [-28.58, 42.73] -11.92 0.364 [-37.63, 13.79]
Q1 -1.90 0.924 [-40.91, 37.11] -7.26 0.611 [-35.27, 20.75]
Lutein
Q3 5.24 0.770 [-29.89, 40.37] -8.71 0.499 [-33.98, 16.57]
Q2 18.51 0.344 [-19.82, 56.84] 6.56 0.640 [-20.96, 34.08]
Q1 -25.41 0.192 [-63.60, 12.77] -17.81 0.204 [-45.27, 9.66]
Zeaxanthin
Q3 37.46 0.020 [5.81, 69.11] 13.33 0.256 [-9.65, 36.32]
Q2 16.92 0.377 [-20.63, 54.47] 1.43 0.918 [-25.77, 28.62]
Q1 -13.47 0.507 [-53.31, 26.37] -11.43 0.437 [-40.28, 17.42]
Lycopene
Q3 -19.11 0.296 [-54.93, 16.72] -1.19 0.927 [-34.80, 24.49]
Q2 -24.02 0.202 [-60.92, 12.88] -14.75 0.275 [-41.20, 11.70]
Q1 -46.00 0.020 [-84.68, -7.32] -28.09 0.047 [-55.87, -0.31]
25-OH Vitamin D -26.57 0.044 [-52.44, -0.71] -17.89 0.059 [-36.45, 0.68]
Transferrin: Ferritin 
Index
42.64 0.064 [-2.41, 87.69] 2.01 0.904 [-30.55, 34.56]
Selenium -38.72 0.004 [-64.84, -12.59] -24.01 0.012 [-42.82, -5.21]
*Models are defined as follows:
     Model C: Adjusted for race, sex, age, BMI category, treatment regimen, presence of TB at baseline,
     viral load at baseline, and baseline hemoglobin







Table 6b. Nutritional biomarkers associated with CD4 recovery at 96 weeks (C & D)*













Biomarker Coefficient P-value 95% CI Coefficient P-value 95% CI
CRP
Q2 4.62 0.798 [-30.73, 39.97] 3.87 0.772 [-22.27, 30.02]
Q3 -37.08 0.040 [-72.45, -1.71] -9.74 0.469 [-36.11, 16.63]
Q4 -62.98 <0.001 [-98.24, -27.72] -23.57 0.081 [-50.05, 2.91]
LPS -22.03 0.082 [-46.86, 2.81] 2.02 0.831 [-16.49, 20.53]
sCD14
Q2 35.70 0.054 [-0.63, 72.02] 26.07 0.054 [-0.41, 52.56]
Q3 27.60 0.138 [-8.85, 64.04] 22.72 0.094 [-3.86, 49.29]
Q4 -2.50 0.890 [-38.10, 33.09] 19.26 0.148 [-6.83, 45.35]
Endocab
Q2 8.55 0.640 [-27.26, 44.35] 4.19 0.752 [-21.85, 30.24]
Q3 13.30 0.466 [-22.47, 49.07] 14.77 0.266 [-11.24, 40.78]
Q4 -0.61 0.974 [-36.41, 35.20] -0.39 0.976 [-26.43, 25.65]
Interferon-γ
Q2 -13.35 0.487 [-50.99, 24.28] 2.49 0.859 [-24.91, 29.89]
Q3 -32.34 0.094 [-70.13, 5.45] -6.32 0.654 [-33.95, 21.30]
Q4 -46.31 0.016 [-84.01, -8.62] 0.355 0.980 [-27.52, 28.22]
IL-6
Q2 -33.52 0.080 [-71.09, 4.05] -2.66 0.850 [-30.25, 24.93]
Q3 -56.00 0.003 [-93.44, -18.57] -5.94 0.676 [-33.78, 21.90]
Q4 -39.81 0.037 [-77.32, -2.31] 0.23 0.987 [-27.48, 27.94]
IP-10
Q2 -13.12 0.495 [-50.86, 24.61] -0.096 0.995 [-27.33, 27.14]
Q3 -27.40 0.157 [-65.32, 10.52] -11.34 0.417 [-38.72, 16.03]
Q4 -29.16 0.130 [-66.91, 8.60] 11.33 0.420 [-16.23, 38.90]
TNF-α
Q2 6.74 0.728 [-31.27, 44.75] 18.93 0.175 [-8.45, 46.30]
Q3 8.73 0.653 [-29.35, 46.81] 15.47 0.268 [-11.92, 42.86]
Q4 -7.97 0.681 [-45.97, 30.03] 18.98 0.176 [-8.51, 46.46]
*Models are defined as follows:
     Model A: Univariate 






Table 7a. Inflammatory biomarkers associated with CD4 recovery at 96 weeks (A & B)*





Biomarker Coefficient P-value 95% CI Coefficient P-value 95% CI
CRP
Q2 9.26 0.603 [-25.61, 44.13] 3.65 0.775 [-21.39, 28.69]
Q3 -16.74 0.358 [-52.40, 18.83] -4.59 0.726 [-30.28, 21.09]
Q4 -32.37 0.088 [-69.56, 4.82] -18.89 0.167 [-45.67, 7.89]
LPS -7.40 0.563 [-32.50, 17.70] 16.69 0.074 [-1.65, 35.03]
sCD14
Q2 29.11 0.108 [-6.37, 64.59] 31.18 0.016 [5.84, 56.51]
Q3 30.08 0.102 [-6.02, 66.18] 30.52 0.020 [4.73, 56.32]
Q4 11.02 0.554 [-25.46, 47.50] 18.70 0.161 [-7.42, 44.83]
Endocab
Q2 -1.20 0.947 [-36.35, 33.95] 0.16 0.990 [-25.01, 25.32]
Q3 11.50 0.520 [-23.56, 46.56] 11.51 0.369 [-13.57, 36.58]
Q4 0.18 0.992 [-35.22, 35.59] -4.88 0.706 [-30.23, 20.46]
Interferon-γ
Q2 -7.54 0.693 [-45.03, 29.95] 0.37 0.978 [-25.99, 26.73]
Q3 -25.47 0.183 [-63.0, 12.05] -11.06 0.412 [-37.50, 15.37]
Q4 -33.42 0.079 [-70.75, 3.91] -0.01 0.999 [-26.48, 26.46]
IL-6
Q2 -29.66 0.119 [-67.0, 7.67] -10.58 0.432 [-36.98, 15.82]
Q3 -52.06 0.007 [-89.84, -14.28] -16.95 0.217 [-43.85, 9.95]
Q4 -30.64 0.109 [-68.11, 6.83] -5.97 0.660 [-32.55, 20.60]
IP-10
Q2 -12.07 0.524 [-49.18, 25.03] 3.75 0.778 [-22.24, 29.73]
Q3 -23.31 0.226 [-61.0, 14.39] -14.90 0.268 [-41.26, 11.45]
Q4 -27.56 0.166 [-66.57, 11.45] -12.96 0.353 [-40.30, 14.38]
TNF-α
Q2 10.04 0.6 [-27.50, 47.58] 11.58 0.389 [-14.75, 37.91]
Q3 22.30 0.248 [-15.56, 60.16] 6.94 0.609 [-19.64, 33.51]
Q4 11.14 0.578 [-28.11, 50.39] 5.07 0.718 [-22.46, 32.61]
*Models are defined as follows:
     Model C: Adjusted for race, sex, age, BMI category, treatment regimen, presence of TB at baseline,
     viral load at baseline, and baseline hemoglobin






Table 7b. Inflammatory biomarkers associated with CD4 recovery at 96 weeks (C & D)*






Odds Ratio P-value 95% CI Odds Ratio P-value 95% CI
Vitamin B12 1.87 0.043 [1.02, 3.44] 1.93 0.034 [1.05, 3.56]
Vitamin B6 1.07 0.707 [0.739, 1.56] 1.09 0.653 [0.749, 1.59]
Vitamin A (Retinol) 0.92 0.854 [0.365, 2.30] 0.92 0.863 [0.367, 2.31]
25(OH)-Vitamin D 1.02 0.921 [0.724, 1.43] 1.01 0.933 [0.722, 1.43]
Ferritin 1.42 0.272 [0.759, 2.66] 1.33 0.379 [0.703, 2.52]
Transferrin Receptor-
Ferritin Index
1.47 0.161 [0.857, 2.54] 1.42 0.212 [0.820, 2.45]
Selenium 1.40 0.056 [0.991, 1.98] 1.43 0.042 [1.01, 2.03]
Odds Ratio P-value 95% CI Odds Ratio P-value 95% CI
Vitamin B12 1.97 0.034 [1.05, 3.69] 2.00 0.031 [1.07, 3.73]
Vitamin B6 0.93 0.706 [0.627, 1.37] 0.94 0.741 [0.632, 1.38]
Vitamin A (Retinol) 0.74 0.538 [0.279, 1.95] 0.72 0.512 [0.274, 1.91]
25(OH)-Vitamin D 1.02 0.915 [0.707, 1.47] 1.02 0.905 [0.709, 1.47]
Ferritin 1.24 0.546 [0.619, 2.47] 1.19 0.626 [0.591, 2.40]
Transferrin Receptor-
Ferritin Index
1.33 0.346 [0.733, 2.42] 1.30 0.394 [0.712, 2.37]
Selenium 1.52 0.028 [1.05, 2.21] 1.54 0.024 [1.06, 2.24]
*Models are defined as follows:
        Model A: Univariate 
        Model B: Adjusted for screening CD4
        Model C: Adjusted for race, sex, age, BMI category, treatment regimen, presence of TB at baseline, 
        viral load at baseline, and baseline hemoglobin
        Model D: Model C + adjustment for screening CD4
Table 8. Association of established nutritional deficiencies and clinical CD4 recovery by 96 weeks*
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APPENDIX A.  
 
Coefficient P-value 95% CI
Baseline CD4 count 
(cells/mm^3)
1.00 <0.001 [0.96, 1.04]
Race/Ethnicity
White
Black -16.11 0.085 [-34.41, 2.20]
Hispanic -9.11 0.371 [-29.08, 10.85]
Asian 25.48 0.008 [6.75, 44.21]
Sex 41.66 <0.001 [33.68, 49.65]
Age (<40) -20.40 <0.001 [-29.25, -11.56]
BMI Category
Underweight
Normal -45.52 <0.001 [-58.14, -32.89]
Overweight -18.20 0.015 [-32.80, -3.60]
Treatment
ddI+FTC+ATV
TDF/FTC+EFV -27.76 <0.001 [-37.88, -17.64]
ZDV/3TC+EFV -20.10 <0.001 [-29.77, -10.42]
TB at baseline 1.39 0.774 [-8.12, 10.90]
Viral load (copies/mL) 1.98x10
-5 0.031 [1.84E-6, 3.77E-5]
Baseline hemoglobin 
(cells/mL) 6.42 <0.001 [4.34, 8.51]







APPENDIX B.  
Biomarker Quartile 1 Quartile 2 Quartile 3 Quartile 4 
α-tocopherol (μmol/L) 5.84 - 18.99 19.04 - 22.55 22.57 - 27.05 27.13 - 62.89 
γ-tocopherol (μmol/L) 0.72 - 1.65 1.68 - 2.46 2.47 - 3.55 3.56 - 15.04 
α-carotene (μmol/L) 0 - 0.02 0.03 - 0.04 0.05 - 0.10 0.11 - 1.82 
β-carotene (μmol/L) 0.02 - 0.11 0.12 - 0.21 0.22 - 0.38 0.39 - 3.42 
β-cryptoxanthin 
(μmol/L) 
0.01 - 0.03 0.04 - 0.06 0.07 - 0.11 0.12 - 0.96 
Lutein (μmol/L) 0.02 - 0.10 0.11 - 0.16 0.17 - 0.25 0.26 - 1.33 
Zeaxanthin (μmol/L) 0.01 - 0.02 0.03 - 0.03 0.04 - 0.05 0.06 - 0.26 
Lycopene (μmol/L) 0.02 - 0.13 0.14 - 0.28 0.29 - 0.45 0.46 - 3.02 
CRP (mg/L) 0.13 - 1.53 1.55 - 3.98 4.19 - 12.95 13.07 - 423.91 
sCD14 (ng/mL) 1.06 - 440.1 442.65 - 2000 2100 - 2700 2800 - 5200 
Endocab IgM 
(MMU/ml) 
3.43 - 28.95 29 - 45.46 45.52 - 67.7 68.64 - 582.53 
Interferon-γ (pg/mL) 0 - 5.69 5.71 - 16.78 16.99 - 45.4 47.97 - 439.93 
IL-6 (pg/mL) 0 - 9.54 9.8 - 25.13 25.41 - 49.78 49.98 - 650.63 
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VOLUNTEER EXPERIENCE         
 
Disaster Action Team Leader, American Red Cross of the Chesapeake Region, Baltimore, MD 
(September 2012—present) 
● Coordinate Red Cross volunteers to cover weekly shifts to respond to emergencies in Baltimore and 
surrounding areas 
 
Disaster Action Team Member, American Red Cross of the Chesapeake Region, Baltimore, MD 
(January 2011—present) 
● Work together with other team members to respond to local disasters, provide clients with immediate 
needs—food, clothing, shelter, etc. 
● Participate in trainings in emergency preparedness, disaster public health, mental health, crisis 
response, and disaster assessment 
● Respond to national disasters in the area (such as hurricanes and floods) as part of the Chesapeake 
region volunteer staff 
 
Member, Alumni Schools Committee, The University of Chicago 
(August 2010—present) 
● Interview prospective students in the Baltimore area, attend local prospective student events in order to 
aid the enrollment efforts of the admissions office 
 
 
RELEVANT SKILLS          
 
● Adept at statistical analysis software (STATA, R, SAS) and mapping programs (ArcGIS) 
● Familiar with database management programs (SQL, REDCap, Microsoft Access) 
● Adept at Microsoft Word, Excel, Powerpoint, and Publisher 
● Proficient in Latin, intermediate-level Spanish. 
 
 
